Cingulate (CING) Accumulated Expenses (2021 - 2026)
Cingulate's (CING) quarterly Accumulated Expenses came in at $563883.0 in Q4 2025, down 45.76% YoY from $1.0 million in Q4 2024, and down 64.76% on a QoQ basis from $1.6 million in Q3 2025.
Cingulate (CING) Accumulated Expenses (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Accumulated Expenses data on file, last reported at $563883.0 in Q4 2025.
- Quarterly Accumulated Expenses fell 45.76% year-over-year to $563883.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $563883.0 (down 45.76% YoY) and the FY2025 annual result came in at $563883.0, down 45.76% from the prior year.
- Accumulated Expenses retreated to $563883.0 in Q4 2025, from $1.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q3 2025 to a low of $140114.0 in Q1 2025.
- A 5-year average of $625462.2 and a median of $593022.0 in 2023 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 297.9% in 2025, down 87.46% in 2025.
- Tracing CING's Accumulated Expenses over 5 years: stood at $601300.0 in 2021, then slumped by 51.38% to $292339.0 in 2022, then soared by 102.85% to $593022.0 in 2023, then surged by 75.31% to $1.0 million in 2024, then tumbled by 45.76% to $563883.0 in 2025.
- The last three Accumulated Expenses figures came in at $563883.0 (Q4 2025), $1.6 million (Q3 2025), and $267984.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Mn |
| Dec 31, 2025 | 563,883.00 |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 267,984.00 |
| Mar 31, 2025 | 140,114.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 402,152.00 |
| Jun 30, 2024 | 383,313.00 |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 593,022.00 |
| Sep 30, 2023 | 175,625.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 699,182.00 |
| Dec 31, 2022 | 292,339.00 |
| Sep 30, 2022 | 670,651.00 |
| Jun 30, 2022 | 311,573.00 |
| Mar 31, 2022 | 756,035.00 |
| Dec 31, 2021 | 601,300.00 |